Recent 8-K filings for NTRA

• August 6, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M

  Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).

• July 6, 2026, 4:05 PM ET leadership materiality 0.30 neutral item 5.02

  Director Monica Bertagnolli resigns from Natera board for new role at National Academy of Medicine

  Resignation effective July 1, 2026, due to new position with the National Academy of Medicine.

• June 16, 2026, 4:08 PM ET leadership materiality 0.35 neutral item 5.02item 9.01 ◈ executive_change

  Natera appoints Thomas Lynch to Board, expanding to 12 directors

  Board increased from 11 to 12 members; Lynch appointed effective June 2, 2026.

• June 16, 2026, 4:06 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×5

  Natera stockholders approve 3.2M share increase to 2015 equity plan

  Stockholders approved amendment to 2015 Equity Incentive Plan, adding 3.2M common shares.

• June 5, 2026, 4:08 PM ET leadership materiality 0.30 neutral item 5.02item 9.01 ◈ executive_change

  Natera appoints Thomas Lynch to board, expands board to 12

  Thomas Lynch appointed as Class I director effective June 2, 2026; term expires at 2028 annual meeting.

• May 7, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt

  Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.

• April 1, 2026, 7:59 PM ET leadership materiality 0.25 neutral item 5.02item 9.01

  Natera appoints Eric Rubin to Board, increasing size to 11

  Eric Rubin appointed as independent Class I director effective March 26, 2026; term expires at 2028 annual meeting.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B

  Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).

• January 12, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook

  Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.

• December 5, 2025, 6:59 PM ET M&A materiality 0.80 positive item 3.02item 8.01item 9.01

  Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts

  All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.

• November 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint

  Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M

  Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).

• June 18, 2025, 7:59 PM ET other material materiality 0.40 neutral item 5.02item 5.07item 9.01

  Natera stockholders approve 3.6M share equity plan increase and reelect three directors

  Directors Baynes, Marcus, and Williams-Brinkley reelected with 91.0M, 79.7M, and 109.0M votes for, respectively.

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M

  Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).

• March 12, 2025, 7:59 PM ET leadership materiality 0.35 neutral item 5.02item 9.01 ◈ executive_change

  Natera appoints Monica Bertagnolli to Board of Directors

  Board increased from 10 to 11; Bertagnolli appointed as Class III director, term expiring at 2027 annual meeting.

• February 27, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B

  Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).

• January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M

  Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.

• December 6, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

  Natera amends employment agreement for Executive Chairman Matthew Rabinowitz

  Rabinowitz's base salary set at 50% of CEO's base salary, with annual cash bonus up to 85% of base salary.

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast

  Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher

  Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.

• July 22, 2024, 7:59 PM ET debt materiality 0.60 neutral item 8.01

  Natera to redeem all $287.5M of 2.25% Convertible Notes due 2027 on Oct 11

  Natera elects to redeem all $287.5M aggregate principal of its 2.25% Convertible Senior Notes due 2027.

• June 18, 2024, 7:59 PM ET other material materiality 0.45 neutral item 5.02item 5.07item 9.01

  Natera shareholders approve amended equity plan adding 6M shares; director Botha reelected narrowly

  Amended 2015 Equity Incentive Plan approved with 85.9M for, 21.5M against; adds 6M shares, extends term 10 years, removes evergreen feature.

• May 9, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow

  Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.

• February 28, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B

  Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.

• January 22, 2024, 6:59 PM ET M&A materiality 0.65 positive item 8.01item 9.01

  Natera acquires Invitae's prenatal and carrier screening assets for $10M upfront

  Upfront cash payment of $10 million to Invitae for reproductive health assets.

• January 9, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera prelim Q4 revenue ~$300M (+38% YoY); FY23 ~$1.07B (+30%), $20M above guidance

  Q4 2023 revenue approx. $300M, up 38% from $217M in Q4 2022.

• November 8, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn

  Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.

• September 7, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Natera prices $250M follow-on offering of 4.55M shares at $55; net proceeds ~$235.4M

  Priced 4,550,000 shares of common stock at $55.00 per share; underwriters granted 30-day option for 682,500 additional shares.

• August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance

  Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).

• June 15, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×2

  Natera shareholders elect directors, ratify auditor, approve say-on-pay at annual meeting

  Elected Class II directors: Rowan Chapman (62.5M for, 30.9M withhold), Herm Rosenman (59.0M for, 34.4M withhold), Jonathan Sheena (57.0M for, 36.4M withhold).

• May 9, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B

  Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).

• April 21, 2023, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  Natera extends Executive Chairman Rabinowitz's term to Jan 2025, $400k salary

  Rabinowitz to serve as Executive Chairman through Jan 31, 2025; base salary $400K per year.

• March 13, 2023, 7:59 PM ET other material materiality 0.70 positive item 7.01

  Natera discloses no exposure to Silicon Valley Bank

  No cash deposits or securities held at Silicon Valley Bank as of March 10, 2023.

• February 28, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B

  Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).

• February 23, 2023, 6:59 PM ET leadership materiality 0.30 neutral item 5.02item 9.01 ◈ executive_change

  Natera appoints Ruth Williams-Brinkley to board, increasing size to 10

  Board expanded from 9 to 10 members; Williams-Brinkley appointed effective March 2, 2023.

• November 16, 2022, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Natera prices $400M follow-on offering of 11.43M shares at $35/share

  Priced 11,430,000 shares at $35.00 per share, with underwriters' option for 1,714,500 additional shares.

• November 8, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q3 revenue $210.6M (+33% YoY), raises FY22 guidance to $810M-$830M

  Total revenues $210.6M, up 33% YoY; test volumes 517,500 (+27% YoY).

• August 15, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Director Monica Bertagnolli resigns from Natera board to lead National Cancer Institute

  Monica Bertagnolli resigned from the Board and all committees effective August 12, 2022.

• August 4, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M

  Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).

• June 1, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Natera shareholders reelect directors, ratify auditor, approve say-on-pay with 48% opposition

  Class I directors elected: Baynes (52M for/24M withheld), Healy (29M for/47M withheld), Marcus (37M for/39M withheld).

• May 5, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Natera Q1 revenue $194.1M (+27.5% YoY), raises 2022 guidance to $790-810M

  Product revenue $190M, up 57.8% YoY; processed 489,300 tests, up 40.5%.

• April 15, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Natera director Todd Cozzens resigns from board effective May 25, 2022

  Todd Cozzens notified board of resignation on April 8, 2022.

• March 14, 2022, 7:59 PM ET other material materiality 0.60 positive item 5.02item 9.01

  Natera executives and board to take stock instead of cash salaries and retainers for 2022

  Executives receive RSUs: CEO Chapman 13,708, CFO Brophy 9,108, COO Schueren 9,634, Sheena 4,141, Rabinowitz 6,763; vest Dec 31, 2022.

• February 24, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M

  Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.

• November 4, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance

  Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).

• August 5, 2021, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M

  Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.

• July 22, 2021, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Natera prices follow-on offering of 4.5M shares at $113/share, expects ~$478.8M net proceeds

  Offering of 4,500,000 shares at $113.00 per share; closing expected July 26, 2021.

• July 20, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01

  Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven

  Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

24 positive 1 negative 23 neutral

source · NTRA on sec.gov